Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

Barrett, Lisa; Rosati, Silvia; García–Retortillo, Montserrat; Wedemeyer, Heiner; Teti, Elisabetta; Hernández, FA Pérez; Selfridge, Marion; Wong, Alexander; Rodríguez‐Tajes, Sergio; Morano-Amado, Luis E.; Brixko, Christian; Jimenez-Mutiloa, E.; O’Loan, Joss; Milella, M.; Campanale, Francesca; Macêdo, Geovani Araújo Dantas; Guerra-Veloz, María Fernanda; Maida, Ivana; Ranieri, Roberto; Martins, A.; Bascia, A.; Buti, María; Fernández-Rodríguez, C.; Conway, B.; Foucher, Juliette; Fagiuoli, S.; Ramji, Alnoor; Fenech, Mary; Ryan, Patricia M.; Borgia, Sergio; Mangia, Alessandra; Mendez-Navarro, J.; Ντάλλα, Ιωάννα; Hernández, Coromoto León; Mertens, Marc; Vanstraelen, Kim; Calvaruso, V.

doi:10.1016/j.aohep.2021.100647

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an RWE study assessing vulnerable HCV patients (people with a mental health disorders, people who were incarcerated, or people who were unhoused) treated with SOF/VEL, 1119 of 1888 (59%) had adherence information available. [13] Adherence was ≤80% among 30 patients (2.3%) and ≤90% among 45 patients (4.0%), with both groups reaching 100% SVR at This article is protected by copyright. All rights reserved.…”

Section: Sofosbuvir/velpatasvirmentioning

confidence: 98%

“…For some treatment regimens, adherence was measured in clinical studies as completion of ≥80% of the treatment, while other studies have applied a threshold of ≥90%. [13][14][15][16] However, a real-world evidence (RWE) study showed that with DAA treatment, those who achieved at least 50% adherence had an overall SVR rate of 99%, demonstrating that suboptimal adherence to DAA treatment may still lead to HCV cure. [17] Different methods have been used to assess patients' adherence to treatment regimens, and this can affect reported adherence rates.…”

Section: Considerations In Evaluating Hcv Therapy Adherencementioning

confidence: 99%

See 1 more Smart Citation

Adherence in Hepatitis C Virus Treatment: What We Know

Flamm,

Mangia

2024

Semin Liver Dis

View full text Add to dashboard Cite

Although therapy with direct-acting antiviral (DAA) agents achieves high HCV cure rates and is forgiving of missed doses, certain patient populations, such as people who inject drugs (PWID), are often denied therapy because of a perceived high risk of nonadherence. However, a relationship between adherence to DAAs for various patient populations and efficacy has not been well defined. The lack of a standardized method for evaluating adherence complicates making comparisons between studies, making it difficult to develop and implement novel measures that may improve adherent behavior. Traditional methods for assessing adherence may overestimate medication adherence, while newer, technology-based methods may assist with accurately assessing and maintaining patient adherence to therapy. Data demonstrate that special populations of patients with HCV, such as PWID, can be successfully treated, with relatively high rates of sustained virologic response (SVR) despite less-than-optimal adherence. While rates of adherence, and subsequently SVR, can be improved, antiviral therapy should not be withheld because of fear of nonadherence. This paper addresses medication adherence and forgiveness of DAA regimens, such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, in different patient populations with HCV. Considerations in evaluating adherence in HCV therapy and available methods for assessing adherence are detailed.

show abstract

Section: Sofosbuvir/velpatasvirmentioning

confidence: 98%